Drug Profile
L 163082
Latest Information Update: 24 Jan 2008
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Ischaemic heart disorder therapies
- Mechanism of Action Angiotensin type 1 receptor antagonists; Angiotensin type 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary artery restenosis
Most Recent Events
- 02 Sep 1998 No-Development-Reported for Coronary artery restenosis in USA (Unknown route)
- 20 Jun 1996 New profile
- 20 Jun 1996 Preclinical development for Coronary artery restenosis in USA (Unknown route)